Skip to content
Menu

TD Cowen Maintains Buy on Genmab, Raises Price Target to $52

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

TD Cowen analyst Yaron Werber maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $43 to $52.

TD Cowen analyst Yaron Werber maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $43 to $52.

Read at benzinga.com